Department of Oncology, San Gerardo Hospital, Monza, Italy.
Department of Oncology, San Gerardo Hospital, Monza, Italy.
Lung Cancer. 2020 Apr;142:120-122. doi: 10.1016/j.lungcan.2020.02.019. Epub 2020 Feb 28.
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability.
We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib.
Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it.
奥希替尼是第三代不可逆表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），与其他 EGFR-TKI 相比，奥希替尼具有更长的无进展生存期和总生存期，且耐受性更好。
我们报告了一例一线奥希替尼治疗期间发生严重再生障碍性贫血的晚期肺腺癌患者。
奥希替尼发生严重血液学毒性极为罕见，但有可能，因此在使用奥希替尼时临床医生应注意血细胞计数的变化。
